Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor

Ying-Yong Hou; Yang Zhou; Shao-Hua Lu; Wei-Dong Qi; Cheng Xu; Jun Hou; Yun-Shan Tan; Brisinda, Giuseppe
April 2009
World Journal of Gastroenterology;5/21/2009, Vol. 15 Issue 15, p1910
Academic Journal
Case Study
Surgical treatments including radical resection and local excision remain the main treatment for primary rectal gastrointestinal stromal tumors (GISTs). However, since patients with high-grade rectal GISTs have a higher risk of tumor recurrence and a shorter life expectancy, neoadjuvant treatment is necessary. In this case report, the efficacy of imatinib mesylate (IM) as a neoadjuvant therapy was assessed in an old man with malignant rectal GIST. The patient received IM preoperative treatment for a short period of one and a half months; at the end of the IM treatment, computed tomography scanning showed a markedly reduced tumor size and cystic changes of the tissue. At that time, a function sphincter-sparing surgery was performed. The histological examination of the resected specimen detected no tumor cells, but residual blood vessels and scattered inflammatory lymphocytes. After surgery, the patient has been followed up without additional IM treatment and remained disease-free for 57 mo. This case indicates that IM neoadjuvant therapy can dramatically improve the prognosis of rectal malignant GIST.


Related Articles

  • Tumores estromales gastrointestinales: diagn�stico y tratamiento. Ac�n-G�ndara, D�bora; Pereira-P�rez, Fernando; Casta�o-Pascual, �ngel; Dur�n-Poveda, Manuel; Antequera-P�rez, Alfonso; Miliani-Molina, Carlos // Cirugia y Cirujanos;ene/feb2012, Vol. 80 Issue 1, p44 

    Background: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal neoplasms of the digestive tract. They originate from the interstitial cells of Cajal and are characterized by the overexpression of KIT protein (tyrosine kinase). Their prognosis has improved significantly with...

  • Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial. Doyon, C.; Sidéris, L.; Leblanc, G.; Leclerc, Y. E.; Boudreau, D.; Dubé, P. // International Journal of Surgical Oncology;2012, p1 

    Purpose. Proven efficacy of imatinib mesylate in gastrointestinal stromal tumour (GIST) has led to its use in advanced disease and, more recently, in adjuvant and neoadjuvant settings. The purpose of this study was to evaluate the optimal neoadjuvant imatinib duration to reduce the morbidity of...

  • Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal. Duffaud, F.; Salas, S.; Huyn, T.; Deville, J. L. // Clinical & Experimental Gastroenterology;2010, Vol. 3, p41 

    Mutations of the KIT gene are the molecular hallmark of most gastrointestinal stromal tumors (GISTs). GIST has become a model for targeted treatment of solid tumors, imatinib becoming the standard first-line treatment of these tumors in the advanced/metastatic phase. Because of the efficacy of...

  • Genomic Grade Index predicts postoperative clinical outcome of GIST. Bertucci, F; Finetti, P; Ostrowski, J; Kim, W K; Kim, H; Pantaleo, M A; Astolfi, A; Polkowski, M; Birnbaum, D // British Journal of Cancer;10/9/2012, Vol. 107 Issue 8, p1433 

    Background:Prognosis of localised gastrointestinal stromal tumour (GIST) is heterogeneous, notably for patients with AFIP intermediate or high risk of relapse, who are candidates to adjuvant imatinib. We hypothesised that gene expression profiles might improve the prognostication and help to...

  • Adherence to Guidelines for Adjuvant Imatinib Therapy for GIST: A Multi-institutional Analysis. Bischof, Danielle; Dodson, Rebecca; Jimenez, M.; Behman, Ramy; Cocieru, Andrei; Blazer, Dan; Fisher, Sarah; Squires, Malcolm; Kooby, David; Maithel, Shishir; Groeschl, Ryan; Gamblin, T.; Bauer, Todd; Karanicolas, Paul; Law, Calvin; Quereshy, Fayez; Pawlik, Timothy // Journal of Gastrointestinal Surgery;Jun2015, Vol. 19 Issue 6, p1022 

    Background: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Adjuvant imatinib therapy improves recurrence-free and overall survival following surgery for patients with high-risk GIST; however, the factors associated with use of...

  • Adjuvant therapy in primary GIST: state-of-the-art. Reichardt, P.; Blay, J-Y.; Boukovinas, I.; Brodowicz, T.; Broto, J. M.; Casali, P. G.; Decatris, M.; Eriksson, M.; Gelderblom, H.; Kosmidis, P.; Le Cesne, A.; Pousa, A. L.; Schlemmer, M.; Verweij, J.; Joensuu, H. // Annals of Oncology;Nov2012, Vol. 23 Issue 11, p2776 

    Background The management of primary gastrointestinal stromal tumours (GISTs) has evolved with the introduction of adjuvant therapy. Recently reported results of the SSG XVIII/AIO trial by the Scandinavian Sarcoma Group (SSG) and the German Working Group on Medical Oncology (AIO) represent a...

  • Imatinib: As Adjuvant Therapy for Gastrointestinal Stromal Tumor. Sanford, Mark; Scott, Lesley J. // BioDrugs;2011, Vol. 25 Issue 3, p191 

    No abstract available.

  • P-0132MANAGEMENT OF GASTROINTESTINAL STROMAL TUMORS : EXPERIENCE OF THE HASSAN II UNIVERSITY HOSPITAL, FEZ, MOROCCO. Amaadour, Lamiae; Benbrahim, Zineb; Afaf, Amarti; Taleb, Khaled AIT; Maazaz, Khaled; Ibrahimi, Adil; Tizniti, Siham; Arifi, Samia; Mellas, Nawfel; El Mesbahi, Omar // Annals of Oncology;Jun2013, Vol. 24 Issue suppl_4, piv73 

    No abstract available.

  • Internistische Therapie gastrointestinaler Stromatumoren. Reichardt, P. // Der Radiologe;Dec2009, Vol. 49 Issue 12, p1128 

    Until recently no active treatment for advanced or metastatic gastrointestinal stroma tumors (GIST) was available. The tyrosine kinase inhibitor imatinib has revolutionized the treatment of this disease and the median overall survival now reaches 5 years. The standard dose of imatinib is 400 mg...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics